← Nektar Therapeutics (NKTR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Nektar Therapeutics (NKTR)
Pharmaceutical Preparations · market cap $2.0B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
18
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Nektar Therapeutics (NKTR) is a San Francisco-based biopharmaceutical company with 137 employees and a ~$2.3B market cap, known for its PEGylation and polymer conjugate platform. Its lead asset, Rezpegaldesleukin, is in Phase 3 for moderate-to-severe atopic dermatitis, with a broader pipeline spanning oncology and immunology. The company has ~10 months of cash runway as of mid-2026, making near-term capital decisions and Phase 3 data critical.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NKTR-214 | Phase 2 | Unspecified Adult Solid Tumor, Protocol Specific |
| Bempegaldesleukin | Phase 2 | Urinary Bladder Neoplasm |
| Rezpegaldesleukin | Phase 3 | Moderate to Severe Atopic Dermatitis |
| LY3471851 | Phase 2 | Systemic Lupus Erythematosus |
| NKTR-102 q14d | Phase 2 | Tumor |
| NKTR-181 | Phase 2 | Osteoarthritis of the Knee |
| NKTR-102 100 mg/m2 | Phase 2 | Tumor |
| NKTR-181 BID tablets | Phase 3 | Low Back Pain |
| NKTR-255 | Phase 2 | Head and Neck Squamous Cell Carcinoma |
| Treatment of Physician's Choice (TPC) | Phase 3 | Locally Recurrent Breast Cancer |
| NKTR-102 145 mg/m2 | Phase 2 | Malignant Solid Tumor |
| Eribulin | Phase 3 | Metastasis |
| NKTR-102 | Phase 3 | Tumor |
| Pegylated Irinotecan | Phase 2 | Stage IV Non-small Cell Lung Cancer (NSCLC) |
| aerosolized vancomycin or gentamicin | Phase 2 | Ventilator Associated Pneumonia |
| Amikacin inhalation solution (BAY41-6551) | Phase 2 | Pneumonia |
| Etirinotecan pegol | Phase 2 | Anaplastic Astrocytomas |
| Dronabinol MDI | Phase 2 | Migraine With Aura |
Price & technical context
3-month
-33.9%
6-month
-37.9%
12-month
-20.2%
52-wk range
$35.12–$100.35
vs 50-day MA
-32.9%
vs 200-day MA
-28.2%
Realized vol
79.8%
Max drawdown
-67.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NKTR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.